The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
Open accessAbstract
We used PET scans with the tracers [18F]fluorodeoxyglucose (FDG) and [11C]raclopride (RACLO) to study glucose metabolism and dopamine D2 receptor binding in the caudate nucleus and putamen of 18 carriers of the Huntington's disease gene mutation (10 asymptomatic subjects and eight untreated symptomatic Huntington's disease patients in an early disease stage). We also performed MRI scans and measured the bicaudate ratio (BCR) in the same subjects. Data were compared with those from nine mutation-negative members of Huntington's disease families and separate groups of age matched controls. The PET scans were repeated 1.5-3 years later in six of the asymptomatic gene carriers. Symptomatic Huntington's disease patients showed a marked reduction of FDG and RACLO uptake in the caudate nucleus and putamen and a significant increase of BCR. Asymptomatic mutation carriers revealed significant hypometabolism in the caudate nucleus and putamen. The RACLO binding was significantly decreased in the putamen. Decrements of caudate nucleus tracer uptake, particularly RACLO, correlated significantly with BCR increases in both symptomatic and asymptomatic gene carriers. In asymptomatic carriers, metabolic and receptor binding decreases were also significantly associated with the CAG repeat number but not with the individual's age. Discriminant function analysis correctly classified clinical and genetic status in 24 of 27 subjects on the basis of their striatal PET values (83% sensitivity and 100% specificity). Three asymptomatic mutation carriers were classified/grouped together with mutation-negative subjects, indicating that these individuals had normal striatal RACLO and FDG uptake. Follow-up PET data from gene-positive subjects showed a significant reduction in the mean striatal RACLO binding of 6.3% per year. Striatal glucose metabolism revealed an overall non significant 2.3% decrease per year. These data indicate that asymptomatic Huntington's disease mutation carriers may show normal neuronal function for a long period of life. These findings also suggest that it may be possible to predict when an asymptomatic gene carrier will develop clinical symptoms from serial PET measurements of striatal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Differential loss of striatal projection neurons in Huntington disease.
Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., & Young, A. B. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5733 · Cited by 839
Quantitative Analysis of D2 Dopamine Receptor Binding in the Living Human Brain by PET
Farde, L., Hall, H., Ehrin, E., & Sedvall, G. (1986) · Science · doi:10.1126/science.2867601 · Cited by 831
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E. C., & Mandel, J.-L. (1995) · Nature Genetics · doi:10.1038/ng0595-104 · Cited by 452
Albin, R. L., Reiner, A., Anderson, K. D., Dure, L. S., Handelin, B., Balfour, R., Whetsell, W. O., Penney, J. B., & Young, A. B. (1992) · Annals of Neurology · doi:10.1002/ana.410310412 · Cited by 368
Reduced Cerebral Glucose Metabolism in Asymptomatic Subjects at Risk for Huntington's Disease
Mazziotta, J. C., Phelps, M. E., Pahl, J. J., Huang, S.-C., Baxter, L. R., Riege, W. H., Hoffman, J. M., Kuhl, D. E., Lanto, A. B., Wapenski, J. A., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160701 · Cited by 314
Cited by
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Mechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428
Onset and rate of striatal atrophy in preclinical Huntington disease
Aylward, E. H., Sparks, B. F., Field, K. M., Yallapragada, V., Shpritz, B. D., Rosenblatt, A., Brandt, J., Gourley, L. M., Liang, K., Zhou, H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000132965.14653.d1 · Cited by 408
Evidence for specific cognitive deficits in preclinical Huntington's disease
Lawrence, A. (1998) · Brain · doi:10.1093/brain/121.7.1329 · Cited by 384
Proteomic and oxidative stress analysis in human brain samples of Huntington disease
Sorolla, M. A., Reverter-Branchat, G., Tamarit, J., Ferrer, I., Ros, J., & Cabiscol, E. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.014 · Cited by 301
Cardoso, F., Seppi, K., Mair, K. J., Wenning, G. K., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70494-x · Cited by 294
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao, J., & Diamond, M. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm213 · Cited by 287
Regional Specificity of Brain Atrophy in Huntington's Disease
Halliday, G. M., McRitchie, D. A., Macdonald, V., Double, K. L., Trent, R. J., & McCusker, E. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6919 · Cited by 271
Social cognition in frontotemporal dementia and Huntington’s disease
Snowden, J. S., Gibbons, Z. C., Blackshaw, A., Doubleday, E., Thompson, J., Craufurd, D., Foster, J., Happé, F., & Neary, D. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(02)00221-x · Cited by 264
Genetics and Neuropathology of Huntington's Disease
Reiner, A., Dragatsis, I., & Dietrich, P. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00014-6 · Cited by 261
Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
The Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Huntington's disease progression
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H. A., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.12.2353 · Cited by 169
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development
Lumsden, A. L., Henshall, T. L., Dayan, S., Lardelli, M. T., & Richards, R. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm138 · Cited by 156
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
Neuroinflammation in Huntington’s Disease: New Insights with 11 C-PBR28 PET/MRI
Lois, C., González, I., Izquierdo-García, D., Zürcher, N. R., Wilkens, P., Loggia, M. L., Hooker, J. M., & Rosas, H. D. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00072 · Cited by 84
Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease
Lerner, R. P., Trejo Martinez, L. D. C. G., Zhu, C., Chesselet, M.-F., & Hickey, M. A. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.01.012 · Cited by 51
Parallel explicit and implicit control of reaching
Mazzoni, P., & Wexler, N. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007557 · Cited by 24
(2006) · PubMed
Metadata
- Authors
- Antonini, A., Leenders, K. L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., Sanchez-Pernaute, R., de Yébenez, J. G., Boesiger, P., Weindl, A., & Maguire, R. P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1996
- Volume
- 119
- Issue
- 6
- Pages
- 2085-2095
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1994536298
- Cited by
- 323
- References
- 36
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.